๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: A Gynecologic Oncology Group study

โœ Scribed by Peter G. Rose; Chunqiao Tian; Michael A. Bookman

Book ID
113962413
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
298 KB
Volume
117
Category
Article
ISSN
0090-8258

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Phase II evaluation of three-day topotec
Phase II evaluation of three-day topotecan in recurrent platinum-sensitive ovarian carcinoma : A Gynecologic Oncology Group study
โœ David Scott Miller; John A. Blessing; Samuel S. Lentz; D. Scott McMeekin ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 79 KB ๐Ÿ‘ 1 views

## Abstract ## BACKGROUND Topotecan, administeredintravenously at a dose of 1.5 mg/m^2^ per day for 5 days every 21 days, is an established regimen in the treatment of recurrent ovarian carcinoma. Alternate dosing strategies have sought to improve toxicity. The authors evaluated the tolerability a